WaveMan
WaveMan · Company
KLRS · Kalaris Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

KLRS Kalaris Therapeutics (KLRS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001754068
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
26
13F, latest reported quarter

What the filings say about KLRS

Insiders, 180 days
+$1.2M net bought
1 buyer

Kalaris Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Kalaris Therapeutics, Inc. insiders bought a net $1.2M of stock across 4 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Samsara BioCapital, L.P.
Director
BUY
2026-05-22 SECtraded 2026-05-20
244,300
$1.2M
-65.5%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 11.0% of the 2,224,147 shares held after it.
  • No other insider bought within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Samsara BioCapital, L.P. bought about $1.2M of KLRS on May 20, 2026; 26 funds added in the latest 13F quarter.
Hagen Brett R
Chief Accounting Officer
SELL
2026-03-23 SECtraded 2026-03-20
1,915
$12.9K
-71.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Mar 26, 2025.
  • No other insider sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Hagen Brett R sold about $12.9K of KLRS on Mar 20, 2026, the largest insider sale at the company on our record; 26 funds added in the latest 13F quarter.
Samsara Opportunity Fund, L.P.
Director
BUY
2026-02-17 SECtraded 2025-12-18
479,847
$5.0M
-82.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 24.2% of the 1,979,847 shares held after it.
  • No other insider bought within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Samsara Opportunity Fund, L.P. bought about $5.0M of KLRS on Dec 18, 2025, the largest insider purchase at the company on our record; 26 funds added in the latest 13F quarter.
Hagen Brett R
Chief Accounting Officer
SELL
2025-03-27 SECtraded 2025-03-26
907
$8.1K
-79.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 47.1% of the 1,925 shares held after it.
  • No other insider sold within 30 days.
  • 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Hagen Brett R sold about $8.1K of KLRS on Mar 26, 2025, the largest insider sale at the company on our record; 26 funds added in the latest 13F quarter.
4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.2M over 180 days
+$1.2M of it by a 10%+ holder
more than 89% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
26 funds bought in last quarter
below 64% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.2% of the float short (float per yahoo 2026-10-27) · 3.5 days to cover · settled 2026-10-15
below 71% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch KLRS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-63.2%12M
-63%-1%+62%+125%2025-102025-122026-022026-042026-062026-082026-10 2025-12-18 · Samsara Opportunity Fund, L.P. bought $5.0M2026-05-20 · Samsara BioCapital, L.P. bought $1.2M2026-03-20 · Hagen Brett R sold $12.9K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns KLRS: institutional holders (13F)

13F holdings, latest reported quarter
SAMSARA BIOCAPITAL, LLC
12,881,175 sh
$52.4M
RTW INVESTMENTS, LP
1,300,000 sh
$5.3M
Alyeska Investment Group, L.P.
572,687 sh
$2.3M
Siren, L.L.C.
435,798 sh
$1.8M
VANGUARD CAPITAL MANAGEMENT LLC
398,712 sh
$1.6M

Congress trades in KLRS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

KLRS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

KLRS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$132.3K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$105.5K position · as of 2026-06-30
0.0%
VIP Disciplined Small Cap Portfolio
$31.8K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$7.0K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$559.1K position · as of 2026-06-30
0.0%
Goldman Sachs Absolute Return Tracker Fund
$32.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.2M bought by insiders over 180 days, 26 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

KLRS financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-79.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-46.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-54.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$46.2M-$51.7M-$199.9M-$171.2M
Net income-$43.4M-$69.2M-$190.4M-$168.7M
EPS (diluted)-2.85-51.77-42.09-2.20
Operating cash flow-$38.4M-$20.7M-$124.5M-$142.1M
Cash$98.1M$1.6M$90.1M$106.1M
SEC XBRL, fiscal years, as known on 2026-10-28

KLRS Stock Sonar score 4/7 axes

Find similar shapesCompare

KLRS ranks highest on insider conviction (72nd percentile) and profitability (44th), and lowest on risk and compliance (31st), among Pharma & Biotech peers.

Profitability
44
Inputs
  • Return on equity-79.9% · 39 pct, sector of 545
  • Return on assets-46.0% · 47 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-54.3% · 47 pct, sector of 576
Insider conviction
72
Inputs
  • Net Form 4 buying (codes P and S), 180d$1.2M · 89 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
36
Inputs
  • Funds adding, latest quarter26 · 36 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
31
Inputs
  • Short interest, % of float+4.2% · 62 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+88.0% · 1 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

KLRS filings, in plain words

Are Kalaris Therapeutics insiders buying or selling KLRS?

In the 180 days to 2026-10-28, Kalaris Therapeutics insiders were net buyers, a net $1.2M across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Kalaris Therapeutics insiders were net buyers of KLRS, a net $1.2M across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $1.2M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies